Jefferies Remains Bullish on Magellan Health (MGLN) Following NDR

November 15, 2016 7:52 AM EST
Get Alerts MGLN Hot Sheet
Price: $78.75 --0%

Rating Summary:
    4 Buy, 3 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade MGLN Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Jefferies reiterated a Buy rating and $78.00 price target on Magellan Health Services (NASDAQ: MGLN) after spending time with management. MGLN's 3Q beat and raise helped alleviate concerns of the steeper than usual 2H earnings ramp. MGLN is expected to issues formal 2017 guidance in a week and Jefferies believes that a $315mm EBITDA projection is conservative.

Analyst David Styblo commented, "We reiterate our Buy rating following an NDR with CEO Barry Smith. Meetings increased visibility on several topics including the pipeline, client retention, and ACA risk. Our projections are conservative and don't include upside from Virginia MLTSS, which would add ~10 points of revenue growth. Despite this month's share price surge, we think MGLN is still undervalued (~20% upside) per our SOTP on Chart 1."

For an analyst ratings summary and ratings history on Magellan Health Services click here. For more ratings news on Magellan Health Services click here.

Shares of Magellan Health Services closed at $65.45 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Jefferies & Co, Earnings

Add Your Comment